Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.…
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio (NASDAQ: BRVE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 20.39 USD on 20 November 2026. Its 52-week range is 16.70 USD to 32.00 USD: the price is 36.3% below the high and 22.1% above the low.
Its market capitalisation is 1.67B USD.
Braveheart Bio reports return on equity of 100.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 348.76M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 45.50 USD is 123.1% above the current price. The next earnings report is expected on 18 March 2027.